graphs presmedic.com [email protected] (917) 856-0582
TRANSCRIPT
Graphs
presmedic.com [email protected] (917) 856-0582
DAS28: DMARD Change and Biologic Groups
Adapted from Bombardier C, et al: Presented at CRA 2010; poster #17.presmedic.com [email protected] (917) 856-0582
Before
0
1
2
3
4
5
6
7
8
Biologic DMARD Change
Mea
n S
core
DAS28: DMARD Change and Biologic Groups
Biologic (baseline)Biologic (6 Mth)
DMARD Change (baseline)DMARD Change (6 Mth)
Adapted from Bombardier C, et al: Presented at CRA 2010; poster #17.presmedic.com [email protected] (917) 856-0582
After
Patient Agreement With Statements Regarding Adherence Support
Adapted from Olszynski W, et al: Presented at CRA 2010; poster #201.presmedic.com [email protected] (917) 856-0582
Before
0 2
25
2 2
20
5 510
3428
19
5963
26
0
10
20
30
40
50
60
70
I feel satisfied with theoverall support I get from
family and friends
I feel satisfied with theoverall support I get from
the HUMIRAPROGRESS program
May family and friendshelp me remember totake my medication
Coh
ort
(%)
Patient Agreement With Statements Regarding Adherence Support
Adapted from Olszynski W, et al: Presented at CRA 2010; poster #201.
Strongly Disagree Disagree Undecided Agree Strongly agree
presmedic.com [email protected] (917) 856-0582
After
Bevacizumab Alone and With Irinotecan: Progression-free Survival
PFS-6BV alone: 42.6%BV + Iri: 50.3%
Adapted from Friedman HS, et al: J Clin Oncol 2009; 27(28):4733-40presmedic.com [email protected] (917) 856-0582
Before
Bevacizumab Alone and With Irinotecan: Progression-free Survival
Adapted from Friedman HS, et al: J Clin Oncol 2009; 27(28):4733-40
0.0
0.2
0.4
0.6
0.8
1.0
0 2 4 6 8 10 12 14
Pro
gre
ssio
n-F
ree
Su
rviv
al(p
rop
ort
ion
)
Time (months)
BV + CPT-11 (n = 82) median PFS 5.6 months (95% CI, 4.4 to 6.2)
PFS-6BV alone: 42.6%BV + Iri: 50.3%
BV (n = 85) median PFS 4.2 months (95% CI, 2.9 to 5.8)
No. at risk85 61 39 26 14 4 1 082 65 47 24 15 7 1 0
presmedic.com [email protected] (917) 856-0582
After
Recurrence by MMR Status:dMMR Attenuated Risk of Recurrence
All Patients Stage II Colon
Risk ratio: 0.53 (95% CI 0.40-0.70) Risk ratio: 0.49 (95% CI 0.36-0.68)
p<0.00001 p<0.00001
MMR, mismatch repair; dMMR, defective mismatch repairAdapted from Hutchins G, et al. J Clin Oncol 28:7s, 2010 (suppl; abstr 3517)
Before
Recurrence by MMR Status:dMMR Attenuated Risk of Recurrence
MMR, mismatch repair; dMMR, defective mismatch repairAdapted from Hutchins G, et al. J Clin Oncol 28:7s, 2010 (suppl; abstr 3517)
Risk ratio: 0.53 (95% CI 0.40-0.70)p<0.00001
Risk ratio: 0.49 (95% CI 0.36-0.68)p<0.00001
All Patients Stage II Colon
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10Years from randomization
% w
ith
recu
rren
ce
At risk:Deficient 218 201 195 189 174 146 112 94 69 47 37Proficient 1695 1563 1405 1286 1127 921 750 608 479 327 214
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10Years from randomization
% w
ith
recu
rren
ceAt risk:Deficient 199 187 181 176 162 136 105 90 67 45 35Proficient 1097 1014 918 850 744 613 501 398 304 204 131
No.Patients
No. EventsObs. Exp.
Deficient 218 25 56.9Proficient 1695 438 406.1
Deficient Proficient
2P < 0.0000131%
14%
2P < 0.00001
27%
11%
No.Patients
No. EventsObs. Exp.
Deficient 199 18 43.8Proficient 1097 245 219.2
Deficient Proficient
After
Rapid Desensitization to Chemotherapy
278 hadno reaction111 had a
mild reaction
24 hada severereaction
67%
27%
6%
Castells, et al. J Allergy Clin Immunol 2008;122:574-80.
Severe: Including at least 1 of:• Chest pain • Changes in BP• Dyspnea • O2 desaturation • Throat tightness
Mild: Absence of any of the above
presmedic.com [email protected] (917) 856-0582
After
Peterson LR et al Circulation 2004; 109: 2192-2196
Effect Of Obesity And Insulin Resistance On Myocardial Substrate Metabolism And Function In Young Women
• Increased hemodynamic load and neurohormonal activation
• Increased FFA uptake, utilization and oxidation • Increased ceramide production and apoptosis • Increased oxidative stress and myocellular injury
• Similar cardiac phenotype as hypertensive heart but different mechanisms
• May help explain greater risk for CHF in women compared to men
presmedic.com [email protected] (917) 856-0582
Before
Effect of Obesity And Insulin Resistance on Myocardial Substrate Metabolism and Function in Young Women
Peterson LR et al Circulation 2004; 109: 2192-2196
Increased hemodynamic load and neurohormonal activation
Increased FFA uptake, utilization and oxidation
Increased ceramide production and apoptosis
Increased oxidative stress and myocellular injury
Similar cardiac phenotype as hypertensive heart but different mechanisms
May help explain greater risk for CHF in women compared to men
0.00.51.01.52.02.53.03.54.04.55.0
MVO
2 (j/g
/min
)
0 20 40 60BMI (kg/m2)
0
5
10
15
20
25
30
35
Effic
ienc
y (%
)
0 20 40 60BMI (kg/m2)
0.00.10.20.30.40.50.6
7,500 10,000 12,500 15,000 17,500
MFA
Up
(mL/
g/m
in)
Glucose AUC (mg/dL x 120 min)
0
100
200
300
400
7,500 10,000 12,500 15,000 17,500
MFA
U (m
mol
/g/m
in)
Glucose AUC (mg/dL x 120 min)
0
100
200
300
400
7,500 10,000 12,500 15,000 17,500
MFA
O (m
L/g/
min
)
Glucose AUC (mg/dL x 120 min)
r = .55P < .005
r = .62P < .001
r = .58P < .005
r = .58P < .0006
r = .40P < .05
A
B
A
B
C
presmedic.com [email protected] (917) 856-0582
After
20050829
Low dose Lasix relieves Dyspnea well and equal to high Dose w.r.t. Dyspnea: VERITAS
presmedic.com [email protected] (917) 856-0582
Before
Low Dose Lasix Relieves Dyspnea Well and Equal to High Dose W.R.T. Dyspnea: VERITAS
3,000
900
2,000
1,000
0
-1,000
-2,000
-3,000
8007006005004003002001000Maximum in-hospital diuretic dose
Dys
pn
ea v
as
presmedic.com [email protected] (917) 856-0582
After
presmedic.com [email protected] (917) 856-0582
Before
Study or Subgroup
AS Control
WeightRisk Ratio
M-H, Random, 95% CIRisk Ratio
M-H, Random, 95% CIEvents Total Events Total
Han 2006 122 1843 391 7372 39.8% 1.25 [1.03, 1.52]
Peters 2009 17 383 922 75333 36.0% 3.63 [2.27, 5.80]
Sukenik 1987 7 40 5 40 24.2% 1.40 [0.48, 4.04]
Total (95% CI) 2266 82745 100.0% 1.88 [0.83, 4.26]
Total events 46 1318
0.2 0.5 2 51Heterogeneity: Tau2 = 0.43; Chi2 = 17.28; df = 2 (P = 0.0002); I3 = 88%Test for overall effect Z = 1.51 (P = 0.13)
presmedic.com [email protected] (917) 856-0582
After
presmedic.com [email protected] (917) 856-0582
Before
ParameterAdjusted Effect Size
(96% CI)Adjusted Treatment Difference,
Units (SD)
ASDAS 0.80 units (0.88)
C-reactive protein 8.61 mg/L (11.59)
Nocturnal back pain 16.41 mm (VAS) (24.83)
Stiffness 13.81 mm (VAS) (22.93)
Back pain 14.73 mm (VAS) (24.48)
Disease Activity Patient Global Assessment 14.51 mm (VAS) (24.16)
Length of stiffness 14.13 mm (VAS) (23.90)
Disease Activity Physician Global Assessment 11.44 mm (VAS) (19.35)
BASDAI 12.08 mm (VAS) (20.93)
ASQoL 2.52 units (4.53)
Level of stiffness 13.56 mm (VAS) (24.81)
Peripheral Joint Arthritis Patient Global Assessment 13.19 mm (VAS) (24.88)
BASR 9.92 mm (VAS) (20.89)
Peripheral Joint Arthritis Physician Global Assessment 7.90 mm (VAS) (16.63)
Derived EQ-50 score 0.11 units (0.24)
BASMI 0.59 mm (VAS) (1.33)
SF-36 PCS 3.70 units (8.55)
SF-36 MCS 3.38 units (9.33)
VAS EQ-5D 6.82 mm (VAS) (20.51)
Modified Schober’s Test 0.49 cm (1.57)
Inter??? distance 4.55 cm (16.47)
HADS total score 1.28 units (5.46)
HADS depression score 0.66 units (3.02)
HADS anxiety score 0.64 units (3.03)
Cervical rotation 2.51 degrees (12.66)
Tender joint count 0.79, n (70 joints) (4.16)
Lateral flexion 0.69 cm (3.68)
Swollen joint count 0.40, N (68 joints) (2.37)
Tragus-to-wall distance 0.28 cm (2.24)
Chest expansion 0.18 cm (3.05)
Occiput-to-wall distance 0.28 cm (4.55)
From an ANCOVA model, adjusted for the endpoint’s baseline and pooled site: adjusted effect size is the adjusted difference between etanercept and sulfasalazine, divided by ANCOVA model-based SD estimate. Effect sizes <0.4 were considered small; 0.4-0.7moderate; and ≥0.7 large. The width of the 95% CI for ASQoL is attributable to the smaller sample size relative to other endpoints.
Sulfasalazine > Etanercept Etanercept > Sulfasalazine
-0.2 0 0.2 0.4 0.6 0.8 1 1.2
presmedic.com [email protected] (917) 856-0582
After
Thank you!Please contact us with questions or to discuss your project
presmedic.com [email protected] (917) 856-0582
presmedic.com [email protected] (917) 856-0582